Cargando…
Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study
BACKGROUND: Throughout 2007 and January 2008, several glitazones health warnings were published on rosiglitazone myocardial infarction risk. The impact of such warnings on glitazones prevalence of utilization has been extensively studied in the United States but only in one European country (England...
Autores principales: | Carracedo-Martínez, Eduardo, Pia-Morandeira, Agustin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989582/ https://www.ncbi.nlm.nih.gov/pubmed/27579167 http://dx.doi.org/10.1177/2050312116653054 |
Ejemplares similares
-
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
por: Niyomnaitham, Suvimol, et al.
Publicado: (2014) -
Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008) -
Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
por: Araki, Takako, et al.
Publicado: (2011) -
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009) -
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
por: Deeg, Mark A., et al.
Publicado: (2008)